Histamine H4 receptor antagonist - JW Pharmaceutical
Alternative Names: Project A5 H4R antagonist - JW PharmaceuticalLatest Information Update: 28 Jul 2023
At a glance
- Originator JW Pharmaceutical
- Class Antiallergics; Eye disorder therapies; Small molecules
- Mechanism of Action Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Allergic conjunctivitis
Most Recent Events
- 18 Jul 2023 Preclinical trials in Age-related macular degeneration in South Korea (unspecified route) prior to July 2023 (JW Pharmaceutical pipeline, July 2023)
- 18 Jul 2023 Preclinical trials in Allergic conjunctivitis in South Korea (unspecified route) prior to July 2023 (JW Pharmaceutical pipeline, July 2023)